Prasugrel for acute coronary syndromes: Faster, more potent, but higher bleeding risk
Prasugrel for acute coronary syndromes: Faster, more potent, but higher bleeding risk
复制标题
DOI：
10.3949/ccjm.76a.09116
复制
发表时间：
2009-12-01
影响因子：
6.1
通讯作者：
Lincoff, A. Michael
中科院分区：
文献类型：
--
作者：
Lazar, Lawrence D.;Lincoff, A. Michael
Prasugrel（有效率）已被批准用于降低急性冠状动脉综合征患者接受经皮冠状动脉介入治疗时血栓并发症的风险。在一项大型临床试验中（N Engl J Med 2007; 357:2001-2005），在这种情况下，普拉格雷优于同类药物氯吡格雷（Plavix）。然而，出血并发症在普拉格雷中更为常见，因此出血风险较高的患者应避免使用该药。
Prasugrel (Effient) has been approved for reducing the risk of thrombotic complications in patients with acute coronary syndromes who are to undergo percutaneous coronary intervention. In a large clinical trial (N Engl J Med 2007; 357:2001-2005), prasugrel was superior to clopidogrel (Plavix), another drug of its class, in this situation. However, bleeding complications were more frequent with prasugrel, and so this drug should be avoide in patients at higher risk of bleeding.